Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma.

[1]  I. Chirivella,et al.  Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients , 2009, Breast Cancer Research and Treatment.

[2]  J. Rosenfeld,et al.  Adjuvant chemotherapy for breast cancer – prognostic impact of relative dose-intensity. , 2009 .

[3]  B. Sousa,et al.  Relative dose intensity reduction in breast cancer adjuvant chemotherapy. , 2009 .

[4]  K. Ohta,et al.  The Impact of Relative Dose Intensity of Rituximab-CHOP on Survival in Diffuse Large B-Cell Lymphoma Patients , 2008 .

[5]  K. Inokuchi,et al.  Importance of Relative Dose Intensity for Survival in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-Like Regimen , 2008 .

[6]  H. Earl,et al.  NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life , 2008, British Journal of Cancer.

[7]  S. Welch,et al.  Delivered relative dose intensity and febrile neutropenia rate with common adjuvant chemotherapy regimens: A review , 2008 .

[8]  Z. Berneman,et al.  Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP , 2008, Annals of Hematology.

[9]  R. Paridaens,et al.  Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study , 2008, Supportive Care in Cancer.

[10]  O. Nanni,et al.  Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis , 2008, Breast Cancer Research and Treatment.

[11]  M. Schwenkglenks,et al.  Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy , 2008, Annals of Hematology.

[12]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[13]  K. Ohta,et al.  The Impact of Relative Dose Intensity (RDI) of CHOP on Outcome of Diffuse Large B-Cell Lymphoma: Results of a Single Center Study. , 2007 .

[14]  W. Brugger,et al.  Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. , 2007, Critical reviews in oncology/hematology.

[15]  G. Lyman,et al.  Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy , 2005, Cancer.

[16]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Farquhar,et al.  High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. , 2007, Cancer treatment reviews.

[18]  C. Desch,et al.  Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. , 2007, Clinical lymphoma & myeloma.

[19]  T. Delozier,et al.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Earl,et al.  Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. , 2006, The New England journal of medicine.

[21]  A. Ceribelli,et al.  Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Chirivella,et al.  Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Lyman,et al.  Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy , 2006, Breast Cancer Research and Treatment.

[24]  R. Paridaens,et al.  Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment , 2006, Supportive Care in Cancer.

[25]  P. Sismondi,et al.  Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer , 2006, Journal of chemotherapy.

[26]  K. Gelmon,et al.  Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. , 2005, The Lancet. Oncology.

[27]  S. Di Cosimo,et al.  Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Farquhar,et al.  High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. , 2005, The Cochrane database of systematic reviews.

[29]  S. Gertler,et al.  Relative dose intensity of FEC100: An analysis of outcomes , 2005 .

[30]  S. Schraub,et al.  Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Friedberg,et al.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.

[33]  R. Otter,et al.  Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study , 2004, Journal of Cancer Research and Clinical Oncology.

[34]  A. Jimeno,et al.  Dose and Dose Intensity Effect of Adjuvant Anthracycline-Based Chemotherapy in Early Breast Cancer: A Retrospective Analysis , 2004, American journal of clinical oncology.

[35]  Y. Bang,et al.  Doxorubicin‐based chemotherapy for diffuse large B‐cell lymphoma in elderly patients , 2003, Cancer.

[36]  G. Lyman,et al.  Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Thomas,et al.  Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients , 2003, British Journal of Cancer.

[38]  G. Kerr,et al.  Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer , 2003, British Journal of Cancer.

[39]  P. Sonneveld,et al.  CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  John Myhre,et al.  CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. , 2003, Blood.

[41]  W. Eiermann,et al.  Maintenance of dose intensity in adjuvant chemotherapy of breast cancer in patients treated outside a clinical trial: Results of a retrospective study , 2003 .

[42]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. Carter,et al.  Chemotherapy Dose Intensity Determination as a Quality of Care Measure for Managed Care Organizations in the Treatment of Early-Stage Breast Cancer , 2002, American journal of medical quality : the official journal of the American College of Medical Quality.

[44]  M. Piccart,et al.  The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  V. Morrison,et al.  Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. , 2001, Oncology.

[46]  G. Budd,et al.  Delivering adjuvant chemotherapy to women with early‐stage breast carcinoma , 2001, Cancer.

[47]  I. Tannock,et al.  Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma , 2001, Cancer.

[48]  V. Morrison,et al.  The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. , 2001, Clinical lymphoma.

[49]  D. Noh,et al.  Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5‐fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma , 2000, Cancer.

[50]  E. Franssen,et al.  Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support. , 1999, Leukemia & lymphoma.

[51]  C. Blomqvist,et al.  Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF , 1999, British Journal of Cancer.

[52]  L. Beex,et al.  Quality of adjuvant chemotherapy in primary breast cancer in a non-trial setting. A comprehensive cancer centre study. The Breast Cancer Group of the Dutch Comprehensive Cancer Centre East (IKO). , 1999, European journal of cancer.

[53]  J. Boyages,et al.  Adjuvant chemotherapy for node-positive breast cancer: a retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil , 1999 .

[54]  A. Goldhirsch,et al.  Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .

[55]  W. Hryniuk,et al.  A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  D A Berry,et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.

[57]  L. Norton.  Evolving concepts in the systemic drug therapy of breast cancer. , 1997, Seminars in oncology.

[58]  M. Gobbi,et al.  Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. , 1997, Blood.

[59]  B. Coiffier,et al.  Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Leukemia & lymphoma.

[60]  E. D. de Vries,et al.  Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. , 1996, Oncology.

[61]  J. Baselga,et al.  Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[63]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[64]  J. Radford,et al.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.

[65]  Umberto Veronesi,et al.  Breast cancer (Third of three parts) , 1992 .

[66]  P. Duffey,et al.  The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[68]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R A Olshen,et al.  Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  G. Bertelli,et al.  Impact of Administration‐Related Factors on Outcome of Adjuvant Chemotherapy for Primary Breast Cancer , 1989, American journal of clinical oncology.

[71]  G. Hortobagyi,et al.  Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  N. Haim,et al.  Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. , 1988, Israel journal of medical sciences.

[73]  Hryniuk Wm.  Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.

[74]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  C. Redmond,et al.  The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. , 1983, Cancer treatment reports.

[77]  J. O'fallon,et al.  A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy , 1982, American journal of clinical oncology.

[78]  B. Hoogstraten,et al.  Combination chemotherapy (CMFVP) versus L‐phenylalanine mustard (L‐PAM) for operable breast cancer with positive axillary nodes. A southwest oncology group study , 1982, Cancer.

[79]  A. Dawson,et al.  Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. , 1980, British journal of clinical pharmacology.

[80]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[81]  R. Greil,et al.  Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy , 2013, Annals of Hematology.

[82]  Gary H Lyman,et al.  Impact of chemotherapy dose intensity on cancer patient outcomes. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[83]  R. Grol,et al.  Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice. , 2002, Anticancer research.

[84]  T. Pieńkowski,et al.  Dose intensity of adjuvant CMF chemotherapy program for breast cancer , 2001 .

[85]  M. Piccart,et al.  Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. , 2001, Anticancer research.

[86]  A. Auvinen,et al.  Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. , 1997, British Journal of Cancer.

[87]  R. Sylvester,et al.  Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. von Pawel,et al.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. , 1993, European journal of cancer.

[89]  Hryniuk Wm.  The importance of dose intensity in the outcome of chemotherapy. , 1988 .

[90]  H. Senn,et al.  Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[91]  H. Mouridsen,et al.  Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[92]  R. K. Knight,et al.  A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[93]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.

[94]  W. McGuire,et al.  Breast Cancer 4 , 1981, Springer US.